Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Monday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE BTX opened at $1.76 on Monday. The firm has a market capitalization of $103.53 million, a price-to-earnings ratio of -0.78 and a beta of 4.61. The stock has a 50 day moving average price of $1.98 and a 200 day moving average price of $1.98. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.